Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters










Database
Language
Publication year range
1.
Br J Cancer ; 85(2): 297-302, 2001 Jul 20.
Article in English | MEDLINE | ID: mdl-11461093

ABSTRACT

Loss of skeletal muscle is a major factor in the poor survival of patients with cancer cachexia. This study examines the mechanism of catabolism of skeletal muscle by a tumour product, proteolysis-inducing factor (PIF). Intravenous administration of PIF to normal mice produced a rapid decrease in body weight (1.55 +/- 0.12 g in 24 h) that was accompanied by increased mRNA levels for ubiquitin, the Mr 14 000 ubiquitin carrier-protein, E2, and the C9 proteasome subunit in gastrocnemius muscle. There was also increased protein levels of the 20S proteasome core and 19S regulatory subunit, detectable by immunoblotting, suggesting activation of the ATP-ubiquitin-dependent proteolytic pathway. An increased protein catabolism was also seen in C(2)C(12)myoblasts within 24 h of PIF addition with a bell-shaped dose-response curve and a maximal effect at 2-4 nM. The enhanced protein degradation was attenuated by anti-PIF antibody and by the proteasome inhibitors MG115 and lactacystin. Glycerol gradient analysis of proteasomes from PIF-treated cells showed an elevation in chymotrypsin-like activity, while Western analysis showed a dose-related increase in expression of MSSI, an ATPase that is a regulatory subunit of the proteasome, with a dose-response curve similar to that for protein degradation. These results confirm that PIF acts directly to stimulate the proteasome pathway in muscle cells and may play a pivotal role in protein catabolism in cancer cachexia.


Subject(s)
Adenosine Triphosphate/metabolism , Blood Proteins/physiology , Muscle, Skeletal/metabolism , Ubiquitins/metabolism , Animals , Blotting, Northern , Blotting, Western , Female , Hydrolysis , In Vitro Techniques , Mice , Proteoglycans
2.
Br J Cancer ; 84(8): 1135-40, 2001 Apr 20.
Article in English | MEDLINE | ID: mdl-11308266

ABSTRACT

A prominent feature of several type of cancer is cachexia. This syndrome causes a marked loss of lean body mass and muscle wasting, and appears to be mediated by cytokines and tumour products. There are several proteases and proteolytic pathways that could be responsible for the protein breakdown. In the present study, we investigated whether caspases are involved in the proteolytic process of skeletal muscle catabolism observed in a murine model of cancer cachexia (MAC16), in comparison with a related tumour (MAC13), which does not induce cachexia. Using specific peptide substrates, there was an increase of 54% in the proteolytic activity of caspase-1, 84% of caspase-8, 98% of caspase-3 151% to caspase-6 and 177% of caspase-9, in the gastrocnemius muscle of animals bearing the MAC16 tumour (up to 25% weight loss), in relation to muscle from animals bearing the MAC13 tumour (1-5% weight loss). The dual pattern of 89 kDa and 25 kDa fragmentation of poly (ADP-ribose) polymerase (PARP) occurred in the muscle samples from animals bearing the MAC16 tumour and with a high amount of caspase-like activity. Cytochrome c was present in the cytosolic fractions of gastrocnemius muscles from both groups of animals, suggesting that cytochrome c release from mitochondria may be involved in caspase activation. There was no evidence for DNA fragmentation into a nucleosomal ladder typical of apoptosis in the muscles of either group of mice. This data supports a role for caspases in the catabolic events in muscle involved in the cancer cachexia syndrome.


Subject(s)
Cachexia/metabolism , Caspases/metabolism , Endopeptidases/metabolism , Muscle, Skeletal/metabolism , Neoplasms, Experimental/complications , Animals , Apoptosis , Blotting, Western , Cachexia/etiology , Cachexia/pathology , Caspase 1/metabolism , Caspase 3 , Caspase 6 , Caspase 8 , Caspase 9 , Cytochrome c Group/metabolism , DNA/genetics , DNA/metabolism , DNA Fragmentation , Mice , Mice, Inbred Strains , Poly(ADP-ribose) Polymerases/metabolism , Substrate Specificity
3.
Appl Environ Microbiol ; 66(5): 1871-6, 2000 May.
Article in English | MEDLINE | ID: mdl-10788353

ABSTRACT

Bradyrhizobium japonicum strain 110spc4 was capable of chemolithoautotrophic growth with carbon monoxide (CO) as a sole energy and carbon source under aerobic conditions. The enzyme carbon monoxide dehydrogenase (CODH; EC 1.2.99.2) has been purified 21-fold, with a yield of 16% and a specific activity of 58 nmol of CO oxidized/min/mg of protein, by a procedure that involved differential ultracentrifugation, anion-exchange chromatography, hydrophobic interaction chromatography, and gel filtration. The purified enzyme gave a single protein and activity band on nondenaturing polyacrylamide gel electrophoresis and had a molecular mass of 230,000 Da. The 230-kDa enzyme was composed of large (L; 75-kDa), medium (M; 28.4-kDa), and small (S; 17.2-kDa) subunits occurring in heterohexameric (LMS)(2) subunit composition. The 75-kDa polypeptide exhibited immunological cross-reactivity with the large subunit of the CODH of Oligotropha carboxidovorans. The B. japonicum enzyme contained, per mole, 2.29 atoms of Mo, 7.96 atoms of Fe, 7.60 atoms of labile S, and 1.99 mol of flavin. Treatment of the enzyme with iodoacetamide yielded di(carboxamidomethyl)molybdopterin cytosine dinucleotide, identifying molybdopterin cytosine dinucleotide as the organic portion of the B. japonicum CODH molybdenum cofactor. The absorption spectrum of the purified enzyme was characteristic of a molybdenum-containing iron-sulfur flavoprotein.


Subject(s)
Aldehyde Oxidoreductases/metabolism , Bradyrhizobium/enzymology , Coenzymes , Multienzyme Complexes/metabolism , Aerobiosis , Aldehyde Oxidoreductases/chemistry , Aldehyde Oxidoreductases/isolation & purification , Bradyrhizobium/growth & development , Carbon Monoxide/metabolism , Chromatography, Gel , Chromatography, Ion Exchange , Flavins/metabolism , Kinetics , Metalloproteins/analysis , Molybdenum Cofactors , Multienzyme Complexes/chemistry , Multienzyme Complexes/isolation & purification , Pteridines/analysis
4.
Cancer Res ; 59(21): 5507-13, 1999 Nov 01.
Article in English | MEDLINE | ID: mdl-10554027

ABSTRACT

The effect of a proteolysis inducing factor (PIF) on protein synthesis and degradation and the modulation of this effect by the polyunsaturated fatty acid, eicosapentaenoic acid (EPA), have been examined using a surrogate model system, C2C12 myoblasts in vitro. After 90 min of incubation, PIF produced a significant inhibition of protein synthesis in a dose-dependent manner, with maximal inhibition at a concentration of 4 nM. The effect was attenuated both by treatment with a monoclonal antibody to PIF and by treatment with insulin at physiological concentrations (1 nM) and below (0.1 nM), but not by EPA (50 microM). The inhibitory effect on protein synthesis was transitory and was not seen after prolonged incubation with PIF. An increased rate of protein degradation was observed in C2C12 myoblasts after addition of PIF, which was also maximal at a concentration of PIF of 4 nM. Higher concentrations of PIF did not produce an increase in protein degradation. Unlike the effect on protein synthesis, the enhanced protein degradation was completely abolished by pretreatment with 50 microM EPA, suggesting that the two effects are mediated by different mechanisms. PIF produced an increased release of [3H]arachidonic acid from prelabeled myoblasts with a dose-response curve parallel to that of protein degradation and with a maximum at 4 nM PIF. Release of [3H] arachidonic acid was completely blocked in cells pretreated with 50 microM EPA, suggesting that the effect was related to protein degradation. The [3H]arachidonic acid was rapidly metabolized to prostaglandins E2 and F2alpha and to 5-, 12-, and 15-hydroxyeicosatetraenoic acids (HETEs). Production of all eicosanoids was attenuated in cells pretreated with EPA. Of all of the metabolites, only 15-HETE produced a significant increase in protein degradation in C2C12 myoblasts with a maximal effect at 30 nM and with a bell-shaped dose-response curve similar to that produced by PIF. These results suggest that PIF enhances protein degradation as a result of an increased production of 15-HETE.


Subject(s)
Blood Proteins/pharmacology , Eicosapentaenoic Acid/pharmacology , Muscle, Skeletal/metabolism , Animals , Arachidonic Acid/biosynthesis , Arachidonic Acid/metabolism , Cell Line , Dose-Response Relationship, Drug , Hydroxyeicosatetraenoic Acids/pharmacology , Insulin/pharmacology , Mice , Protein Synthesis Inhibitors/pharmacology , Proteins/drug effects , Proteins/metabolism , Proteoglycans
5.
Br J Cancer ; 78(7): 850-6, 1998 Oct.
Article in English | MEDLINE | ID: mdl-9764574

ABSTRACT

A proteolysis-inducing factor (PIF) isolated from a cachexia-inducing murine tumour (MAC16) produced a decrease in body weight (1.6 g, P < or = 0.01 compared with control subjects) within 24 h after i.v. administration to non-tumour-bearing mice. Weight loss was associated with significant decreases in the weight of the spleen and soleus and gastrocnemius muscles, with no effect on the weight of the heart or kidney and with an increase in weight of the liver. Protein degradation in isolated soleus muscle was significantly increased in mice bearing the MAC16 tumour. To define which proteolytic pathways contribute to this increase, soleus muscles from mice bearing the MAC16 tumour and non-tumour-bearing animals administered PIF were incubated under conditions that modify different proteolytic systems. In mice bearing the MAC16 tumour, there were increases in both cathepsin B and L, and the Ca2+-dependent lysosomal and ATP-dependent pathways were found to contribute to the increased proteolysis; whereas, in PIF-injected animals, there was activation only of the ATP-dependent pathway. Further studies in mice bearing the MAC16 tumour have provided evidence for increased levels of ubiquitin-conjugated proteins and increased mRNA levels for the 14 kDa ubiquitin carrier protein E2 and the C9 proteasome subunit in gastrocnemius muscle, suggesting activation of the ATP-ubiquitin-dependent proteolytic pathway. A monoclonal antibody to PIF attenuated the enhanced protein degradation in soleus muscle from mice bearing the MAC16 tumour, confirming that PIF is responsible for the loss of skeletal muscle in cachectic mice.


Subject(s)
Blood Proteins/pharmacology , Endopeptidases/metabolism , Muscle Proteins/drug effects , Muscle, Skeletal/drug effects , Neoplasm Proteins/metabolism , Animals , Cachexia/metabolism , Cathepsin B/metabolism , Cathepsin L , Cathepsins/metabolism , Cysteine Endopeptidases , Female , Mice , Mice, Inbred Strains , Muscle Proteins/metabolism , Muscle, Skeletal/metabolism , Organ Size/drug effects , Proteoglycans , Tumor Cells, Cultured/metabolism
6.
Biochim Biophys Acta ; 1397(3): 257-61, 1998 May 11.
Article in English | MEDLINE | ID: mdl-9582432

ABSTRACT

The pca structural genes encode enzymes that participate in the conversion of protocatechuate to succinate and acetylcoenzyme A. A 3. 05-kb region of the Bradyrhizobium japonicum strain USDA110 genome has been characterized, which contains the pcaB, pcaD and pcaC genes. The predicted protein sequences of the three genes have extensive homologies with beta-carboxy-cis,cis-muconate cycloisomerase (PcaB), beta-ketodiapate enol-lactone hydrolase (PcaD), and gamma-carboxymuconolactone decarboxylase (PcaC), respectively, from Acinetobacter calcoaceticus and Pseudomonas putida. The DNA sequence revealed that the pca genes are probably arranged in a single transcriptional unit, pcaBDC, similar to that described in P. putida. A pcaB deletion mutant constructed by marker exchange mutagenesis lost the ability to use 4-hydroxybenzoate or protocatechuate as the only carbon source, demonstrating functionality of the characterized genes in catabolism of hydroxyaromatics by B. japonicum. Furthermore, 4-hydroxybenzoate and protocatechuate became toxic for the pcaB mutant, indicating that hydroxyaromatics catabolism serves both nutritional and detoxifying purposes.


Subject(s)
Genes, Bacterial , Parabens/metabolism , Rhizobiaceae/genetics , Rhizobiaceae/metabolism , Amino Acid Sequence , Base Sequence , Benzoates/metabolism , Benzoic Acid , Biodegradation, Environmental , Carboxy-Lyases/genetics , Carboxy-Lyases/metabolism , Carboxylic Ester Hydrolases/genetics , Carboxylic Ester Hydrolases/metabolism , Chromosome Mapping , DNA, Bacterial/genetics , Gene Deletion , Intramolecular Lyases/genetics , Intramolecular Lyases/metabolism , Molecular Sequence Data , Open Reading Frames
7.
Br J Cancer ; 76(8): 1035-40, 1997.
Article in English | MEDLINE | ID: mdl-9376263

ABSTRACT

An antigen of apparent molecular weight of 24,000, reactive with a murine monoclonal antibody, has been isolated from a cachexia-inducing tumour (MAC 16) and has been shown to initiate muscle protein degradation in vitro using isolated soleus muscle. Administration of this material to female NMRI mice (20 g) produced a pronounced depression in body weight (2.72 +/- 0.14 g; P<0.005 from control) over a 24 h period. This weight loss was attenuated in mice pretreated with the monoclonal antibody (0.06 +/- 0.26 g over 24 h) and occurred without a reduction in food and water intake. There was no change in body water composition, and the major contribution to the decrease in body weight was a decrease in the non-fat carcass dry weight (mainly lean body mass). The plasma levels of glucose and most amino acids were also significantly depressed. The decrease in lean body mass was accounted for by an increase (by 50%) in protein degradation and a decrease (by 50%) in protein synthesis in gastrocnemius muscle. Protein degradation was significantly decreased and protein synthesis increased to control values in mice pretreated with the monoclonal antibody. Protein degradation initiated in vitro with the proteolysis-inducing factor was abolished in mice pretreated with eicosapentaenoic acid (EPA), which had been shown to prevent muscle wastage in mice bearing the MAC16 tumour. Protein degradation was associated with a significant elevation of prostaglandin E2 production by isolated soleus muscle, which was inhibited by both the monoclonal antibody and EPA. These results suggest that this material may be the humoral factor mediating changes in skeletal muscle protein homeostasis during the process of cancer cachexia in animals bearing the MAC16 tumour, and could potentially be involved in other cases of cachexia.


Subject(s)
Antigens, Neoplasm/pharmacology , Muscle Proteins/drug effects , Muscle Proteins/metabolism , Amino Acids/blood , Animals , Antigens, Neoplasm/isolation & purification , Body Weight/drug effects , Cachexia/chemically induced , Cachexia/etiology , Cachexia/metabolism , Chromatography, Affinity , Female , Homeostasis/drug effects , Mice , Mice, Inbred Strains , Molecular Weight , Muscle, Skeletal/drug effects , Muscle, Skeletal/metabolism , Neoplasms, Experimental/chemistry , Neoplasms, Experimental/complications
8.
Br J Cancer ; 76(5): 606-13, 1997.
Article in English | MEDLINE | ID: mdl-9303359

ABSTRACT

Urine from cancer patients with weight loss showed the presence of an antigen of M(r) 24,000 detected with a monoclonal antibody formed by fusion of splenocytes from mice with cancer cachexia. The antigen was not present in the urine of normal subjects, patients with weight loss from conditions other than cancer or from cancer patients who were weight stable or with low weight loss (1 kg month(-1)). The antigen was present in the urine from subjects with carcinomas of the pancreas, breast, lung and ovary. The antigen was purified from urine using a combination of affinity chromatography with the mouse monoclonal antibody and reversed-phase high-performance liquid chromotography (HPLC). This procedure gave a 200,000-fold purification of the protein over that in the original urine extract and the material isolated was homogeneous, as determined by silver staining of gels. The N-terminal amino acid sequence showed no homology with any of the recognized cytokines. Administration of this material to mice caused a significant (P<0.005) reduction in body weight when compared with a control group receiving material purified in the same way from the urine of a normal subject. Weight loss occurred without a reduction in food and water intake and was prevented by prior administration of the mouse monoclonal antibody. Body composition analysis showed a decrease in both fat and non-fat carcass mass without a change in water content. The effects on body composition were reversed in mice treated with the monoclonal antibody. There was a decrease in protein synthesis and an increase in degradation in skeletal muscle. Protein degradation was associated with an increased prostaglandin E2 (PGE2) release. Both protein degradation and PGE2 release were significantly reduced in mice pretreated with the monoclonal antibody. These results show that the material of M(r) 24,000 present in the urine of cachectic cancer patients is capable of producing a syndrome of cachexia in mice.


Subject(s)
Cachexia/physiopathology , Cachexia/urine , Neoplasms/physiopathology , Adenocarcinoma/physiopathology , Adult , Aged , Amino Acid Sequence , Animals , Body Composition , Breast Neoplasms/physiopathology , Carcinoma, Hepatocellular/physiopathology , Cholangiocarcinoma/physiopathology , Colonic Neoplasms/physiopathology , Dinoprostone/metabolism , Female , Humans , Liver Neoplasms/physiopathology , Male , Mice , Mice, Inbred Strains , Middle Aged , Neoplasm Staging , Neoplasms/pathology , Neoplasms/urine , Ovarian Neoplasms/physiopathology , Pancreatic Neoplasms/physiopathology , Peptide Fragments/chemistry , Proteinuria , Rectal Neoplasms/physiopathology , Reference Values
SELECTION OF CITATIONS
SEARCH DETAIL
...